Andrea Pirzkall
Overview
Explore the profile of Andrea Pirzkall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1609
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma S, Suchomel J, Yanez E, Yost E, Liang X, Zhu R, et al.
Br J Clin Pharmacol
. 2019 Apr;
85(8):1751-1760.
PMID: 30973970
Aims: Navoximod (GDC-0919, NLG-919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1), developed to treat the acquired immune tolerance associated with cancer. The primary objectives of this study were...
2.
Jung K, LoRusso P, Burris H, Gordon M, Bang Y, Hellmann M, et al.
Clin Cancer Res
. 2019 Feb;
25(11):3220-3228.
PMID: 30770348
Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells...
3.
Emens L, Davis S, Oliver S, Lieu C, Reddy A, Solomon S, et al.
JAMA Ophthalmol
. 2018 Nov;
137(1):96-100.
PMID: 30383154
Importance: Checkpoint inhibition in cancer immunotherapy related to T-cell-driven mechanisms of action associated with acute macular neuroretinopathy (AMN) and diffuse retinal venulitis, an adverse event not previously described, is reported...
4.
Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian N, et al.
J Immunother Cancer
. 2018 Jun;
6(1):61.
PMID: 29921320
Background: Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919)...
5.
Hill A, Findlay M, Burge M, Jackson C, Garcia Alfonso P, Samuel L, et al.
Clin Cancer Res
. 2018 Mar;
24(10):2276-2284.
PMID: 29506988
Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Metastatic colorectal cancer (mCRC) patients with ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerable toxicity. Mandatory...
6.
Lieu C, Hidalgo M, Berlin J, Ko A, Cervantes A, LoRusso P, et al.
Oncologist
. 2017 Jun;
22(9):1024-e89.
PMID: 28592615
Lessons Learned: Cobimetinib and duligotuzumab were well tolerated as single agents and in combination with other agents.The cobimetinib and duligotuzumab combination was associated with increased toxicity, most notably gastrointestinal, and...
7.
Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, et al.
Front Oncol
. 2016 Nov;
6:232.
PMID: 27843803
Background: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), inhibits signaling from all...
8.
Jimeno A, Machiels J, Wirth L, Specenier P, Seiwert T, Mardjuadi F, et al.
Cancer
. 2016 Aug;
122(24):3803-3811.
PMID: 27525588
Background: This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual-action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3)...
9.
Fredrickson J, Serkova N, Wyatt S, Carano R, Pirzkall A, Rhee I, et al.
Magn Reson Med
. 2016 Feb;
77(2):814-825.
PMID: 26918893
Purpose: To assess the feasibility of acquiring vessel size imaging (VSI) metrics using ferumoxytol injections and stock pulse sequences in a multicenter Phase I trial of a novel therapy in...
10.
Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein Jr G, et al.
Clin Cancer Res
. 2015 Jun;
21(11):2462-70.
PMID: 26034219
Purpose: The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of...